Trial Profile
A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs BMS 986178 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Cyclophosphamide; DPV 001
- Indications Bladder cancer; Non-small cell lung cancer; Renal cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 29 Jul 2021 Status changed from recruiting to completed.
- 04 Nov 2020 Results (n=165) published in the Clinical Cancer Research
- 23 Sep 2020 Planned End Date changed from 15 Aug 2022 to 14 Oct 2024.